Skip to main content Skip to main content
Go to homepage
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

A study evaluating safety and efficacy of Debio 4326

A study evaluating the safety and efficacy of Debio 4326 in treating precocious puberty in children receiving gonadotropin-releasing hormone agonist

Description:

Please view the study at Clinicaltrials.gov for complete information.

Interested in participating?
We are currently recruiting
Study Sponsor:

Debiopharm International S.A

Full IRB Study Title:
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)
IRB Study ID:
2024-051
If you are interested in this study or have questions about your child's eligibility, please contact:

Naveen Uli, MD -  Phone: 330-543-3276; email: nuli@akronchildrens.org
JoAnn Katz, BSN – Phone: 330-543-0690; email: jkatz@akronchildrens.org

Lead Investigator
Naveen Uli, MD

Medical Director, Center for Diabetes and Endocrinology; Pediatric Endocrinologist

Starting Locations:
Career Opportunities
Legal:
Mobile App:

Akron Children's Anywhere:

About Akron Children's

While we are ranked among the best children's hospitals in the country, it's our compassionate approach to treatment that makes us truly exceptional. Through a combination of revolutionary treatments and extraordinary patient experiences, our care does more than heal. It brings the entire family together for emotional support and understanding across multiple locations to reach you in the community where you live. Learn more...

Akron Children's
One Perkins Square, Akron, Ohio 44308-1062
330-543-1000 • webmaster@akronchildrens.org
An Equal Opportunity Employer
Copyright © 2020, Akron Children's. All Rights Reserved.
  • Magnet Recongnition
  • Newsweek: World's Best Hospitals - 2023
  • Newsweek: World's Best Hospitals - Pediatrics 2023

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.